10-K · February 17, 2026
Halozyme positions itself as a leader in subcutaneous (SC) drug delivery via its ENHANZE technology (rHuPH20) and has expanded its platform with Hypercon and Surf Bio; the company recorded strong 2025 revenue driven by…
Earnings analysis · 10-Q
HALO earnings analysis
Filed May 11, 2026 · Our reading of the company's report
The latest report
Halozyme Therapeutics, Inc. reported strong Q1 2026 results, achieving revenue of $376.7 million and diluted EPS of $1.22, exceeding consensus estimates of $358.8 million and $1.51, respectively. The company maintained…
Read full summary
Halozyme Therapeutics, Inc. reported strong Q1 2026 results, achieving revenue of $376.7 million and diluted EPS of $1.22, exceeding consensus estimates of $358.8 million and $1.51, respectively. The company maintained its full-year revenue guidance between $1.71 billion and $1.81 billion, indicating continued growth momentum.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.22
What stood out
-
Revenue Growth of 42% YOY
Halozyme's revenue reached $376.7 million, a 42% increase compared to $265 million in Q1 2025.
-
Above Consensus EPS Estimates
The reported diluted EPS of $1.22 surpassed the estimated $1.51 for the quarter.
-
Strong Royalty Revenue Increase
Total royalties increased to $240.7 million, up 43% from the prior year, driven by strong sales of partner products.
-
Increased Cash Position
Cash and cash equivalents rose to $318.6 million as of March 31, 2026.
-
Operating Cash Flow Increase
Net cash provided by operating activities was $180.1 million, up from $154.2 million in Q1 2025.
-
New Share Repurchase Program
A new share repurchase program was authorized to buy back up to $1 billion by December 31, 2028.
What to watch
-
Rising Litigation Costs
Increased legal expenditures due to ongoing patent infringement litigation.
-
Decline in Other Royalty Products
Price erosion expected on older ENHANZE partner products like Herceptin and MabThera.
-
Dependence on Pipeline Success
Revenue growth is heavily reliant on the success of upcoming product launches and collaborations.
Management's outlook
Full year revenue guidance reiterated: $1.71B-$1.81B with growth anticipated.
Earlier filings 4
10-Q · August 6, 2024
Halozyme reported Q2 total revenues of $231.353M (up $10.315M, +4.7% vs Q2 2023 $221.038M) with diluted EPS of $0.72 (vs $0.56 in Q2 2023). Gross margin expanded to ~82.9% and operating margin widened to ~50.7%…
10-Q · May 7, 2024
Halozyme reported Q1 (period ended March 31, 2024) revenue of $195.9M, up from $162.1M a year ago, driven by higher royalties and collaborative revenue. Operating income rose to $95.5M (operating margin ~48.8%) and GAAP…
10-Q · August 9, 2022
Halozyme reported Q2 revenue of $152.365M, up 11.7% year-over-year, driven by higher royalties and product sales, but GAAP diluted EPS declined to $0.16 from $0.62 a year ago. Operating income fell sharply to $34.060M…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.